TEVA

Teva Pharmaceutical Industries Limited [TEVA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

TEVA Stock Summary

Earnings have grown 6.16% per last year.

EPS has been increasing for the past 3 quarters (Quarter statements)

Became profitable this year

Has a high level of debt. Debt-to-Equity ratio of 2.68 is considered high.

Earnings are expected to fall -100% next year

TEVA has less than 1 year of cash runway

Top 10 Correlated ETFs

TEVA

Top 10 Correlated Stocks

TEVA

In the News

TEVA Financial details

Company Rating

Buy

Market Cap

14.91B

Income

-559M

Revenue

15.85B

Book val./share

6.7

Cash/share

2.88

Dividend

Dividend %

Employees

35K

Optionable

Shortable

Yes

Earnings

08 May 2024

P/E

-26.67

Forward P/E

PEG

3.42

P/S

0.94

P/B

1.99

P/C

4.44

P/FCF

17.71

Quick Ratio

0.54

Current Ratio

1.02

Debt / Equity

2.68

LT Debt / Equity

2.27

EPS (TTM)

-0.47

EPS next Y

EPS next Q

EPS this Y

-76.42%

EPS next Y

EPS next 5Y

EPS last 5Y

-11.48%

Revenue last 5Y

-1.27%

Revenue Q/Q

15.77%

EPS Q/Q

474.23%

SMA20

-7.14%

SMA50

8.33%

SMA100

44.44%

Inst Own

43.3%

Inst Trans

1.01%

ROA

-1%

ROE

-8%

ROC

0.03%

Gross Margin

48%

Oper. Margin

Profit Margin

-4%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

7.09-14.47

52W High

-8.68%

52W Low

+82.64%

RSI

Rel Volume

0.73

Avg Volume

10.5M

Volume

7.7M

Perf Week

-7.69%

Perf Month

-6.75%

Perf Quarter

54.59%

Perf Half Y

46.28%

Beta

1.062

Volatility

0.3%, 0.4%

Prev Close

-3%

Price

12.785

Change

-3.44%

TEVA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	15.48	15.21	14.41	13.45	14.16
Net income per share	-0.92	-3.64	0.38	-2.12	-0.5
Operating cash flow per share	0.49	1.11	0.72	1.43	1.22
Free cash flow per share	0.38	0.58	0.21	0.94	0.75
Cash per share	1.81	1.99	1.96	2.52	2.88
Book value per share	12.81	9.16	9.33	7.11	6.71
Tangible book value per share	-19.26	-16.88	-14.76	-13.7	-12.9
Share holders equity per share	12.81	9.16	9.33	7.11	6.71
Interest debt per share	25.81	24.99	22.25	20.29	18.93
Market cap	10.69B	10.57B	8.83B	10.12B	11.68B
Enterprise value	36.06B	34.79B	30.12B	28.88B	28.61B
P/E ratio	-10.7	-2.65	21.17	-4.3	-20.9
Price to sales ratio	0.63	0.63	0.56	0.68	0.74
POCF ratio	19.87	8.69	11.06	6.37	8.54
PFCF ratio	25.52	16.56	37.4	9.72	13.87
P/B Ratio	0.77	1.05	0.86	1.28	1.56
PTB ratio	0.77	1.05	0.86	1.28	1.56
EV to sales	2.14	2.09	1.9	1.94	1.81
Enterprise value over EBITDA	11.22	7.55	6.65	7.04	6.7
EV to operating cash flow	67.02	28.61	37.75	18.17	20.91
EV to free cash flow	86.06	54.53	127.63	27.72	33.98
Earnings yield	-0.09	-0.38	0.05	-0.23	-0.05
Free cash flow yield	0.04	0.06	0.03	0.1	0.07
Debt to equity	1.96	2.63	2.28	2.73	2.68
Debt to assets	0.48	0.52	0.49	0.49	0.46
Net debt to EBITDA	7.9	5.25	4.7	4.57	3.97
Current ratio	0.98	0.99	1.14	1.05	1.02
Interest coverage	3.4	3.17	3.02	2.9	0.42
Income quality	7.08	-0.3	1.75	-0.66	-2.22
Dividend Yield	0	0	0	0	0
Payout ratio	-0.05	0	0	0	0
Sales general and administrative to revenue	0.07	0.07	0.07	0.08	0.07
Research and developement to revenue	0.06	0.06	0.06	0.06	0.06
Intangibles to total assets	0.63	0.58	0.58	0.54	0.52
Capex to operating cash flow	-0.22	-0.48	-0.7	-0.34	-0.38
Capex to revenue	-0.01	-0.03	-0.04	-0.04	-0.03
Capex to depreciation	-0.29	-0.37	-0.42	-0.42	-0.46
Stock based compensation to revenue	0	0.01	0.01	0.01	0.01
Graham number	16.24	27.4	8.91	18.42	8.68
ROIC	0.05	0.08	0.06	0.07	0.02
Return on tangible assets	-0.05	-0.19	0.02	-0.12	-0.03
Graham Net	-31.13	-29.01	-26.27	-25.07	-24.63
Working capital	-210M	-159M	1.55B	582M	238M
Tangible asset value	-21.02B	-18.49B	-16.26B	-15.21B	-14.44B
Net current asset value	-28.94B	-26.57B	-23.85B	-23.26B	-22.87B
Invested capital	1.96	2.63	2.28	2.73	2.68
Average receivables	5.75B	5.13B	4.56B	4.11B	3.55B
Average payables	1.79B	1.74B	1.72B	1.79B	2.24B
Average inventory	4.58B	4.41B	4.11B	3.83B	3.93B
Days sales outstanding	122.68	100.38	104.11	90.39	78.51
Days payables outstanding	67.06	71.75	74.29	86.61	115.82
Days of inventory on hand	172.61	179.91	168.22	175.94	178.98
Receivables turnover	2.98	3.64	3.51	4.04	4.65
Payables turnover	5.44	5.09	4.91	4.21	3.15
Inventory turnover	2.11	2.03	2.17	2.07	2.04
ROE	-0.07	-0.4	0.04	-0.3	-0.07
Capex per share	-0.11	-0.53	-0.51	-0.49	-0.47

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	3.5	3.28	3.46	3.43	3.98
Net income per share	-1.1	-0.18	-0.77	0.07	0.38
Operating cash flow per share	0.88	-0.13	0.29	0	1.06
Free cash flow per share	0.75	-0.25	0.18	-0.13	0.95
Cash per share	2.52	1.92	2.38	2.01	2.88
Book value per share	7.11	7.05	6.3	6.18	6.7
Tangible book value per share	-13.69	-13.59	-13.53	-13.29	-12.88
Share holders equity per share	7.11	7.05	6.3	6.18	6.7
Interest debt per share	19.63	19.1	19	18.36	18.17
Market cap	10.13B	9.87B	8.43B	11.43B	11.7B
Enterprise value	28.89B	28.76B	26.78B	29.48B	28.63B
P/E ratio	-2.07	-12.03	-2.44	35.73	6.82
Price to sales ratio	2.61	2.7	2.17	2.97	2.63
POCF ratio	10.41	-68.05	26.03	2.29K	9.88
PFCF ratio	12.19	-34.75	41.14	-79.4	10.99
P/B Ratio	1.28	1.26	1.2	1.65	1.56
PTB ratio	1.28	1.26	1.2	1.65	1.56
EV to sales	7.44	7.86	6.91	7.66	6.42
Enterprise value over EBITDA	27.54	35.38	27.36	28.21	19.73
EV to operating cash flow	29.69	-198.35	82.66	5.9K	24.18
EV to free cash flow	34.77	-101.27	130.64	-204.74	26.88
Earnings yield	-0.12	-0.02	-0.1	0.01	0.04
Free cash flow yield	0.08	-0.03	0.02	-0.01	0.09
Debt to equity	2.73	2.68	2.98	2.93	2.68
Debt to assets	0.49	0.48	0.49	0.48	0.46
Net debt to EBITDA	17.88	23.24	18.74	17.27	11.67
Current ratio	1.05	1.1	1.02	1	1.02
Interest coverage	3.03	1.96	-2.41	1.27	3.27
Income quality	-0.78	0.61	-0.36	0.06	2.73
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.07	0.08	0.08	0.07	0.07
Research and developement to revenue	0.05	0.06	0.06	0.07	0.05
Intangibles to total assets	0.54	0.55	0.53	0.53	0.52
Capex to operating cash flow	-0.15	0.96	-0.37	-29.8	-0.1
Capex to revenue	-0.04	-0.04	-0.03	-0.04	-0.03
Capex to depreciation	-0.46	-0.46	-0.4	-0.53	-0.45
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.01
Graham number	13.26	5.4	10.45	3.15	7.59
ROIC	0.03	0.02	-0.02	0.01	0.02
Return on tangible assets	-0.06	-0.01	-0.04	0	0.02
Graham Net	-25.05	-25.17	-25.01	-24.77	-24.59
Working capital	582M	1.09B	245M	31M	238M
Tangible asset value	-15.21B	-15.15B	-15.15B	-14.9B	-14.44B
Net current asset value	-23.26B	-23.34B	-23.3B	-23.15B	-22.87B
Invested capital	2.73	2.68	2.98	2.93	2.68
Average receivables	3.71B	3.57B	3.49B	3.46B	3.4B
Average payables	1.76B	2.13B	2.44B	2.39B	2.44B
Average inventory	3.85B	3.98B	4.11B	4.08B	4.04B
Days sales outstanding	85.64	84.44	82.13	79.13	68.82
Days payables outstanding	80.37	103.07	108.41	102.65	114.74
Days of inventory on hand	163.26	178.27	177.62	182.39	177.31
Receivables turnover	1.05	1.07	1.1	1.14	1.31
Payables turnover	1.12	0.87	0.83	0.88	0.78
Inventory turnover	0.55	0.5	0.51	0.49	0.51
ROE	-0.15	-0.03	-0.12	0.01	0.06
Capex per share	-0.13	-0.12	-0.11	-0.13	-0.11

TEVA Frequently Asked Questions

What is Teva Pharmaceutical Industries Limited stock symbol ?

Teva Pharmaceutical Industries Limited is a IL stock and trading under the symbol TEVA

What is Teva Pharmaceutical Industries Limited stock quote today ?

Teva Pharmaceutical Industries Limited stock price is $12.785 today.

Is Teva Pharmaceutical Industries Limited stock public?

Yes, Teva Pharmaceutical Industries Limited is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 10.5M
Market Capitalization 14.91B
Employee 35K
CEO Mr. Richard D. Francis
Headquarters Tel Aviv,IL
IPO Date 1982-02-16
Website https://www.tevapharm.com

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.